|
1.
|
|
Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial. 2023/05
|
|
2.
|
|
Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient-Derived Xenograft Models of Uterine Carcinosarcoma and Its Association with Clinical Efficacy. 2023/06
|
|
3.
|
|
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. 2024/01
|
|
4.
|
|
Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma. 2023/09
|
|
5.
|
|
Discordances in expression of human epidermal growth factor receptor 2 between primary and metastatic uterine carcinosarcoma: A proposal for HER2-targeted therapy specimen selection. 2023/08
|
|
6.
|
|
Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study. 2012/01
|
|
7.
|
|
Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer. 2014/11
|
|
8.
|
|
The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients. 2015
|
|
9.
|
|
Advanced Mucinous Adenocarcinoma Arising from a Mature Cystic Teratoma: A Case Report and Literature Review. 2016
|
|
10.
|
|
Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. 2016/02
|
|
11.
|
|
The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin. 2016/03
|
|
12.
|
|
Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group. 2016/06
|
|
13.
|
|
Drug induced interstitial lung disease in oncology phase I trials. 2016/12
|
|
14.
|
|
A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer. 2017/01
|
|
15.
|
|
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study. 2017/01
|
|
16.
|
|
Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors. 2017/09
|
|
17.
|
|
Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy. 2017/11
|
|
18.
|
|
Utility of Bayesian Single-Arm Design in New Drug Application for Rare Cancers in Japan: A Case Study of Phase 2 Trial for Sarcoma. 2018/05
|
|
19.
|
|
PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system. 2018/08
|
|
20.
|
|
Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma: A case report. 2018/10
|
|
21.
|
|
A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study). 2019/10
|
|
22.
|
|
Subclinical thiamine deficiency identified by preoperative evaluation in an ovarian cancer patient: Diagnosis and the need for preoperative thiamine measurement. 2019/10
|
|
23.
|
|
Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma. 2020
|
|
24.
|
|
Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment. 2020/09
|
|
25.
|
|
HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix. 2020/10
|
|
26.
|
|
Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer. 2020/12
|
|
27.
|
|
Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors. 2021
|
|
28.
|
|
Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy. 2021/06
|
|
29.
|
|
Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis. 2021/07
|
|
30.
|
|
Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives. 2021/10
|
|
31.
|
|
Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience. 2021/12
|
|
32.
|
|
Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial Sarcoma. 2022
|
|
33.
|
|
Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study. 2022/01
|
|
34.
|
|
Association between effector-type regulatory T cells and immune checkpoint expression on CD8+ T cells in malignant ascites from epithelial ovarian cancer. 2022/04
|
|
35.
|
|
Diagnostic value of tumor markers in identifying favorable or unfavorable subsets in patients with cancer of unknown primary: a retrospective study. 2022/04
|
|
36.
|
|
High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer. 2022/11
|
|
37.
|
|
High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective study. 2022/11
|
|
38.
|
|
Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer. 2023
|
|
39.
|
|
Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy. 2023/01
|
|
40.
|
|
Changes in HER3 expression profiles between primary and recurrent gynecological cancers. 2023/02
|
|
41.
|
|
Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer. 2023/02
|
|
42.
|
|
A case of vasculogenic mesenchymal tumor in the mediastinum: whole-exome sequencing reveals origin from pre-existing germ cell tumor. 2023/05
|
|
43.
|
|
Development of a Detection System for ESR1 Mutations in Circulating Tumour DNA Using PNA-LNA-Mediated PCR Clamping. 2023/06
|
|
44.
|
|
Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy. 2023/07
|
|
45.
|
|
Mismatch Repair Protein Expression in Endometrial Cancer: Assessing Concordance and Unveiling Pitfalls in Two Different Immunohistochemistry Assays. 2023/08
|
|
46.
|
|
Uterine Leiomyosarcoma Masquerading as a Malignant Perivascular Epithelioid Cell Tumor: A Diagnostic Challenge. 2023/08
|
|
47.
|
|
Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer. 2023/12
|
|
48.
|
|
Therapeutic target biomarkers of patient-derived xenograft models of gastric-type cervical adenocarcinoma. 2023/12
|
|
49.
|
|
Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression. 2024/03
|
|
50.
|
|
Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis. 2024/05
|
|
51.
|
|
Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis. 2024/05
|
|
52.
|
|
Trop-2 expression and the tumor immune microenvironment in cervical cancer. 2024/05
|
|
53.
|
|
Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers. 2024/05/01
|
|
54.
|
|
Trop-2 expression and the tumor immune microenvironment in cervical cancer. 2024/05/08
|
|
55.
|
|
Folate Receptor Alpha Expression and the Tumor Immune Microenvironment in Patients with Cervical Cancer. 2024/06/12
|
|
56.
|
|
HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma. 2024/07/02
|
|
57.
|
|
Efficacy and safety of nivolumab monotherapy in patients with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR Trial/NCCH1510). 2024/07/30
|
|
58.
|
|
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine. 2024/08/14
|
|
59.
|
|
The efficacy and safety of lenvatinib plus pembrolizumab therapy in patients with uterine carcinosarcoma. 2024/10
|
|
60.
|
|
Development of Antibody–Drug Conjugates for Malignancies of the Uterine Corpus: A Review 2025/02
|
|
61.
|
|
Establishing a comprehensive panel of patient-derived xenograft models for high-grade endometrial carcinoma: molecular subtypes, genetic alterations, and therapeutic target profiling. 2025/04/07
|
|
Display 5 items
|
|
Display all(61)
|
